

INTRODUCTION	XXI
STUDY GOALS AND OBJECTIVES.....	XXI
REASONS FOR DOING THIS STUDY	XXI
SCOPE OF REPORT	XXI
INTENDED AUDIENCE.....	XXII
METHODOLOGY	XXIII
INFORMATION SOURCES.....	XXIII
ABOUT THE AUTHOR.....	XXIII
RELATED BCC RESEARCH REPORTS.....	XXIII
BCC ONLINE SERVICES.....	XXIII
DISCLAIMER	XXIV
 SUMMARY.....	 XXV
<i>SUMMARY TABLE GLOBAL VACCINE MARKET: REVENUE</i>	
<i>FORECAST BY TECHNOLOGY SEGMENTS THROUGH 2013</i>	
<i>(\$ MILLIONS)</i>	XXVI
<i>SUMMARY FIGURE GLOBAL VACCINE MARKET: REVENUE</i>	
<i>FORECAST BY TECHNOLOGY SEGMENTS 2003-2013</i>	
<i>(\$ MILLIONS)</i>	XXVI
 OVERVIEW	 1
VACCINE DEFINITION	1
<i>TABLE 1 EXISTING HUMAN VACCINES IN THE GLOBAL MARKET</i>	1
HISTORY	2
<i>TABLE 2 HUMAN VACCINES: MORBIDITY AND DEVELOPMENT</i>	3
<i>TABLE 2 (CONTINUED)</i>	4
<i>TABLE 2 (CONTINUED)</i>	5
<i>TABLE 2 (CONTINUED)</i>	6
CLASSIFICATION OF VACCINES BY IMMUNOGEN.....	7
INACTIVATED OR ATTENUATED	7
TOXOID	8
LIVE AVIRULENT BACTERIN.....	8
SUBUNIT VACCINES.....	8
CONJUGATE VACCINES.....	9
DNA VACCINES.....	9
RECOMBINANT VECTOR VACCINES.....	9
CLASSIFICATION OF VACCINES BY APPLICATION.....	10
PROPHYLACTIC VACCINES.....	10
Polio Vaccines	10
Funding Scenario.....	11
<i>TABLE 3 FUNDING SCENARIO FOR ERADICATING POLIO</i>	
<i>(\$ MILLIONS)</i>	12
<i>TABLE 4 TYPES OF POLIO VACCINES</i>	12
Rotavirus Vaccines	13

Typhoid Vaccine.....	13
Oral Typhoid Vaccine (Ty21a).....	14
Varicella Vaccines.....	15
Hepatitis B Vaccine	16
Hib Vaccine	16
<i>TABLE 5 VARIOUS FORMULATIONS OF HIB VACCINE.....</i>	<i>17</i>
<i>TABLE 6 COMBINATIONS OF HEP B AND HIB</i>	<i>17</i>
Influenza	17
Cost-Effectiveness of Influenza Vaccination.....	18
<i>TABLE 7 LOSS DUE TO HUMAN INFLUENZA MORBIDITY.....</i>	<i>18</i>
Influenza Recommendation for China	19
<i>TABLE 8 CHINESE GOVERNMENT RECOMMENDATION FOR FLU VACCINATION.....</i>	<i>19</i>
<i>TABLE 9 DOSE REQUIREMENT IN CHINA—FLU VACCINES, 2002- 2006 (MILLION DOSES)</i>	<i>19</i>
<i>TABLE 10 SEASONAL INFLUENZA VACCINE PRODUCTION ESTIMATES</i>	<i>20</i>
THERAPEUTIC VACCINES.....	20
Cancer Vaccines.....	20
Antigen/Adjuvant Vaccines	21
Whole Cell Tumor Vaccines.....	22
Dendritic Cell (DC) Vaccines.....	22
Viral Vectors and DNA Vaccines.....	22
Idiotype Vaccines	22
Idiotype Vaccines (Continued)	23
Quality Control and Release Testing.....	24
Sterility Testing	24
<i>TABLE 11 CANCER VACCINES IN DEVELOPMENT</i>	<i>25</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>26</i>
<i>TABLE 12 PROTEIN- OR PEPTIDE-BASED CANCER VACCINES IN CLINICAL DEVELOPMENT.....</i>	<i>26</i>
<i>TABLE 13 CELL-BASED VACCINES IN DEVELOPMENT</i>	<i>26</i>
Human Immunodeficiency Virus (HIV).....	27
Human ... (Continued).....	28
<i>TABLE 14 VACCINES IN DEVELOPMENT FOR HIV</i>	<i>29</i>
Malaria Vaccines	30
Challenges in Developing a Malaria Vaccine	30
<i>TABLE 15 VACCINES IN DEVELOPMENT FOR MALARIA</i>	<i>30</i>
<i>TABLE 15 (CONTINUED).....</i>	<i>31</i>
COMBINATION VACCINES	31
CONCERNS WITH COMBINATION VACCINES.....	32
<i>TABLE 16 ADVANTAGES OF COMBINATION VACCINES.....</i>	<i>33</i>
ANIMAL VACCINES.....	33
ANIMAL VACCINES (CONTINUED)	34

CLASSIFICATION OF VETERINARY VACCINES	35
<i>FIGURE 1 TYPES OF ANIMAL VACCINES</i>	35
Feline Vaccines	35
<i>TABLE 17 FACTORS DETERMINING CHOICE OF FELINE VACCINE</i>	36
Routine Feline Vaccines	36
Canine Core Vaccines	36
Canine Noncore Vaccines ¹⁰	36
POULTRY VACCINES	37
Live, Attenuated Vaccines.....	37
Inactivated Vaccines.....	37
<i>TABLE 18 VACCINE ADMINISTRATION METHODS FOR POULTRY</i>	37
<i>TABLE 19 CLASSIFICATION BASED ON THE ROUTE OF ADMINISTRATION</i>	38
<i>TABLE 20 COMMERCIAL POULTRY VACCINES</i>	39
<i>TABLE 20 (CONTINUED)</i>	40
<i>TABLE 20 (CONTINUED)</i>	41
<i>TABLE 20 (CONTINUED)</i>	42
<i>TABLE 20 (CONTINUED)</i>	43
<i>TABLE 20 (CONTINUED)</i>	44
<i>TABLE 20 (CONTINUED)</i>	45
<i>TABLE 20 (CONTINUED)</i>	46
<i>TABLE 20 (CONTINUED)</i>	47
AQUACULTURE VACCINES	47
<i>TABLE 21 VACCINES LICENSED FOR AQUACULTURE WORLDWIDE</i>	48
<i>TABLE 21 (CONTINUED)</i>	49
<i>TABLE 22 AQUACULTURE NEEDS — REGION BASED</i>	49
<i>TABLE 22 (CONTINUED)</i>	50
VACCINATION SCHEDULE.....	50
<i>TABLE 23 EFFECT OF MODIFICATION OF VACINATION SCHEDULES</i>	51
RISKS OF CHANGES TO SCHEDULES	51
DESIGNING AN IMMUNIZATION SCHEDULE.....	51
ISSUES TO BE CONSIDERED WHILE PLANNING TO INTRODUCE A NEW VACCINE.....	52
Disease Burden and Cost	52
Epidemiology of the Disease and Morbidity and Mortality	52
<i>TABLE 24 VACCINE DELIVERY: TECHNOLOGY IMPACT THROUGH MODIFICATION OF IMMUNIZATION SERVICES</i>	53
VACCINE ADVERSE REACTIONS	54
<i>TABLE 25 COMMON ADVERSE REACTIONS</i>	54
VACCINE SAFETY DATALINK (VSD) PROJECT.....	54
<i>TABLE 26 MANAGED CARE ORGANIZATION (MCO) SITES</i>	55
<i>TABLE 27 SIGNIFICANT CORRELATIONS BETWEEN VACCINES AND ADVERSE REACTIONS</i>	55

<i>TABLE 28 CURRENT PRIORITY STUDIES</i>	56
RAPID CYCLE ANALYSIS (RCA) PROJECT	56
VACCINE SAFETY RESEARCH	57
<i>TABLE 29 RESEARCH ACTIVITIES OF THE CDC OFFICE OF SCIENCE COORDINATION AND INNOVATION</i>	57
REPORTING SIDE EFFECTS	57
THE VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS)	58
<i>TABLE 30 ADVERSE EVENT INFORMATION FROM VAERS</i>	58
<i>TABLE 30 (CONTINUED)</i>	59
<i>TABLE 31 ADVERSE EVENTS WITH VACCINES</i>	60
<i>TABLE 32 COMMON SIDE EFFECTS OF VACCINES</i>	61
<i>TABLE 33 COMPONENTS AND VACCINES THAT INCREASE IGE LEVELS</i>	61
<i>TABLE 34 SIDE EFFECTS OF SOME COMPONENTS OF VACCINES</i>	61
<i>TABLE 34 (CONTINUED)</i>	62
Aluminum	62
<i>TABLE 35 SIDE EFFECTS OF ALUMINUM IN VACCINES</i>	62
VACCINE CONCERNS	63
Thimerosal (Ethylmercury) as an Additive in Vaccines	63
Unsubstantiated Link between MMR Vaccine and Autism	63
VACCINE TECHNOLOGY REVIEW	64
VACCINE MANUFACTURE — AN OVERVIEW	64
ESSENTIAL COMPONENTS FOR SUCCESSFUL DEVELOPMENT OF A LARGE-SCALE MANUFACTURING PROCESS.....	64
CELL CULTURE-BASED VACCINE PRODUCTION.....	65
Advantages of Cell Culture Technologies over Egg-based Manufacturing Methods.....	66
REVERSE GENETICS MANUFACTURING	66
GENETIC REASSORTMENT	67
PLANT-BASED VACCINE MANUFACTURING	68
OVERVIEW OF CURRENT GOOD MANUFACTURING PRACTICES (CGMPS)	68
<i>TABLE 36 VACCINE MANUFACTURING PROCESSES AND THEIR IMPERATIVES</i>	68
<i>TABLE 37 TENTATIVE TIMEFRAME OF VACCINE PRODUCTION PROCESS</i>	69
VACCINE MEDIA	69
<i>TABLE 38 VACCINE PRODUCTION — CELL CULTURE</i>	69
Madin-Darby Bovine Kidney (MDBK) Media	69
M 3553 — Madin-Darby Bovine Kidney Growth Medium Serum-Free (MDBK-GM-SF).....	70

M 0682 Madin-Darby Bovine Kidney Maintenance Medium (MDBK-MM-PF)	70
Madin-Darby Canine Kidney (MDCK) Media	71
<i>TABLE 39 ADVANTAGES OVER TRADITIONAL SERUM</i>	
<i>SUPPLEMENTED MEDIA</i>	71
M 3803 — Madin-Darby Canine Kidney Medium.....	72
M 3678 Madin-Darby Canine Kidney Medium	72
Titerhigh Chick Embryo Fibroblast (CEF) Medium	73
Titerhigh Chick Embryo Fibroblast (CEF) Medium	73
VACCINE COMPANION PRODUCTS AND MEDIUM	
SUPPLEMENTS	73
Antioxidant Supplement (1000x)	74
Cell Freezing Medium—DMSO	74
Dulbecco’s Phosphate Buffered Saline Modified	74
Dulbecco’s Phosphate Buffered Saline (D-PBS)	74
L-Glutamine Solution, 200 Mm	74
Hank’s Balanced Salt Solution Modified	75
Polyamine Supplement (1,000x)	75
Trypsin-EDTA Solution (1x)	75
Trypsin Inhibitor Solution (1x)	75
VACCINE PURIFICATION	76
CHROMATOGRAPHY — VACCINE PURIFICATION	77
PLASMID PURIFICATION.....	77
Disposable Technologies Enhance Plasmid Purification	77
STEPS FOR CLINICAL STUDIES	78
PRECLINICAL SAFETY TESTING	78
Candidate Vaccines: Preclinical Safety Testing.....	79
Qualification of Testing Facility: Good Laboratory Practices (GLP)-Capable Facility	79
Protocol Design	79
Protocol ... (Continued).....	80
Protocol ... (Continued).....	81
Protocol ... (Continued).....	82
VACCINE ADJUVANTS	83
<i>TABLE 40 ADVANTAGES OF ADJUVANTS</i>	83
<i>TABLE 41 DEFINITIVE IMPACT OF ADJUVANTS</i>	84
ALUMINIUM ADJUVANTS	84
<i>TABLE 42 VACCINES WITH ALUMINUM ADJUVANTS</i>	85
<i>TABLE 43 ADJUVANT TYPES</i>	85
COLD CHAIN SYSTEMS.....	86
TEMPERATURE MONITORING	86
<i>FIGURE 2 A TYPICAL COLD CHAIN</i>	87
<i>TABLE 44 EFFECT OF TEMPERATURE ON VACCINES</i>	88
<i>TABLE 45 VACCINE STORAGE GUIDELINES</i>	88

<i>TABLE 46 PREVENTIVE MEASURES TO PREVENT MISHAP</i>	88
<i>TABLE 47 VACCINE INVENTORY CONTROL</i>	89
VACCINE VIAL MONITORS.....	89
ACTIVE AND PASSIVE COLD CHAIN SYSTEMS.....	89
Active and Passive Cold ... (Continued).....	90
PATENT ANALYSIS	91
<i>TABLE 48 MAJOR U.S. PATENTS ISSUED FOR VACCINES</i>	91
<i>TABLE 48 (CONTINUED)</i>	92
<i>TABLE 48 (CONTINUED)</i>	93
<i>TABLE 48 (CONTINUED)</i>	94
<i>TABLE 48 (CONTINUED)</i>	95
<i>TABLE 48 (CONTINUED)</i>	96
<i>TABLE 48 (CONTINUED)</i>	97
<i>TABLE 48 (CONTINUED)</i>	98
<i>TABLE 48 (CONTINUED)</i>	99
<i>TABLE 48 (CONTINUED)</i>	100
<i>TABLE 48 (CONTINUED)</i>	101
<i>TABLE 48 (CONTINUED)</i>	102
<i>TABLE 48 (CONTINUED)</i>	103
<i>FIGURE 3 U.S. PATENT TREND ANALYSIS: HUMAN AND ANIMAL</i> <i>VACCINE PATENTS, 2003-2007</i>	104
<i>FIGURE 4 EUROPEAN PATENT TREND ANALYSIS: HUMAN AND</i> <i>ANIMAL VACCINE PATENTS, 2003-2007</i>	105
<i>TABLE 49 USPTO — ANIMAL VACCINES, 2007</i>	106
<i>TABLE 49 (CONTINUED)</i>	107
<i>TABLE 50 EUROPEAN PATENTS, 2005-2007</i>	108
<i>TABLE 50 (CONTINUED)</i>	109
<i>TABLE 50 (CONTINUED)</i>	110
<i>TABLE 50 (CONTINUED)</i>	111
<i>TABLE 50 (CONTINUED)</i>	112
CLINICAL TRIALS	112
<i>TABLE 51 COUNTRY ATTRACTIVENESS INDEX FOR CLINICAL</i> <i>TRIALS, 2007</i>	112
<i>TABLE 52 PIPELINE CANDIDATES — VACCINES</i>	113
TUBERCULOSIS	114
1. Study: T Cell Turnover Following Vaccination with MVA85A.....	114
2. Study: Phase I Trial of an Ltk63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85b-Esat6) (Tmuva-01)	114
3. Study: The Effect of Bacille Calmette Guerin (BCG) Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants.	115
3. Study: The Effect of ... (Continued)	116

4. Study: The Safety and Immunogenicity of a TB Vaccine; MVA85A in Healthy Volunteers Who Are Infected with HIV.....	117
5. Study: Screening of Healthy Volunteers for Clinical Trials of Vaccines to Prevent Infectious Diseases.	117
HIV.....	118
1. Study: Screening HIV-Infected Patients for Vaccine Studies	118
2. Study: A Study of MVA85A in Asymptomatic Volunteers Infected with TB, HIV, or Both	119
3. Study: Should Low Birth Weight Infants Be Vaccinated with BCG Vaccine at Birth in Developing Countries?.....	120
CANCER.....	121
1. Study: Vaccine Maintenance Treatment for Nonsmall Cell Lung Cancer.....	121
2. Study: Cancer Vaccine Study for Unresectable Stage III Nonsmall Cell Lung Cancer.....	122
3. Study: Safety, Immunogenicity and Preliminary Efficacy Study of Recombinant Human EGF-Rp64k/Montanide ISA 51 Vaccine for Patients with Nonsmall Cell Lung Cancer (NSCLC) After Receiving Conventional First Line Chemotherapy.....	123
4. Study: Vaccine Therapy in Treating Patients with Stage III, Stage IV, or Relapsed Nonsmall Cell Lung Cancer Treated with First Line Chemotherapy	124
5. Study: DNP-Modified Autologous Tumor Cell Vaccine for Resectable Nonsmall Cell Lung Cancer	125
6. Study: Vaccine Therapy in Treating Patients with Stage IIIB or Stage IV Nonsmall Cell Lung Cancer Who Have Finished First Line Chemotherapy	126
7. Study: Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Nonsmall Cell Lung Cancer.....	127
8. Study: Vaccine Therapy in Treating Patients with Advanced Refractory or Recurrent Nonsmall Cell Lung Cancer.....	128
9. Study: Vaccine Therapy and GM-CSF in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, Nonsmall Cell Lung Cancer, or Mesothelioma	129
RECENT TECHNOLOGICAL BREAKTHROUGHS.....	130
DNA VACCINES.....	130
DNA Vaccines (Continued).....	131
DNA Vaccines (Continued).....	132

Challenge Studies in Primates	133
<i>TABLE 53 NEW AGE VACCINES FOR SPECIFIC DISEASES</i>	134
MARKER VACCINES.....	135
Minimum Demands to Vaccination	135
Demands on the Companion Discriminatory Test.....	135
Marker Vaccines in Disease Control.....	135
Criterion for Use of Marker Vaccines	136
<i>TABLE 54 ADVANTAGES OF THE USE OF MARKER VACCINES</i>	136
<i>TABLE 55 DISADVANTAGES OF THE USE OF MARKER VACCINES</i>	136
Use of Marker Vaccines — Economical Considerations	137
<i>TABLE 56 SIGNIFICANT RESEARCH WORK ON MARKER VACCINES</i>	137
PROTEINS AS VACCINES IN THE FUTURE.....	138
REGULATORY OVERVIEW	139
<i>TABLE 57 NATIONAL REGULATORY AUTHORITIES (NRAS) AND NATIONAL CONTROL LABORATORIES (NCLS) IN COUNTRIES PRODUCING VACCINES PREQUALIFIED FOR PURCHASE BY UNITED NATIONS AGENCIES</i>	139
<i>TABLE 57 (CONTINUED)</i>	140
<i>TABLE 57 (CONTINUED)</i>	141
<i>TABLE 58 SOME GUIDELINES AND REQUIREMENTS RELEVANT TO EVALUATION OF VACCINES AND THEIR PUBLISHING AUTHORITIES</i>	142
<i>TABLE 58 (CONTINUED)</i>	143
<i>TABLE 58 (CONTINUED)</i>	144
<i>TABLE 58 (CONTINUED)</i>	145
REGULATIONS GOVERNING HUMAN VACCINES IN THE UNITED STATES.....	146
<i>FIGURE 5 OVRR — ORGANIZATION CHART</i>	146
<i>FIGURE 6 REGULATORY ISSUES UNDER OVRR'S AMBIT</i>	147
<i>FIGURE 7 STAGES OF REVIEW AND REGULATION</i>	148
CMC DEVELOPMENT.....	148
CMC Development (Continued)	149
<i>FIGURE 8 CMC DEVELOPMENT PROCESS</i>	150
CURRENT GOOD MANUFACTURING PRACTICES (CGMPS).....	150
REGULATION FOR PANDEMIC VACCINES	150
<i>FIGURE 9 FDA ROLE THROUGHOUT PANDEMIC VACCINE DEVELOPMENT, EVALUATION, AND AVAILABILITY</i>	151
<i>TABLE 59 REGULATORY ISSUES IN VACCINE DEVELOPMENT IN THE U.S.</i>	151
REGULATIONS GOVERNING VETERINARY VACCINES IN THE UNITED STATES.....	152
REGULATIONS GOVERNING VACCINES IN THE EUROPEAN UNION	152

PREPAREDNESS FOR PANDEMICS AND SPEEDING UP REGULATIONS.....	152
Highlights of European Preparedness for Pandemics or Other Emergencies.....	152
Highlights of U.S. Preparedness for Pandemics or Other Emergencies	153
OPPORTUNITIES TO OPTIMIZE THE REGULATORY PROCESS FOR VACCINES.....	153
OPPORTUNITIES TO OPTIMIZE...(CONTINUED)	154
KEY TRENDS — GROWTH DRIVERS AND INHIBITORS	155
GROWTH DRIVERS.....	155
“OMICS” TECHNOLOGIES DRIVE THE VACCINE INDUSTRY.....	155
DEVELOPMENT OF TECHNOLOGIES THROUGHOUT VACCINE VALUE CHAIN.....	155
GREATER NUMBER OF VACCINES IN THE NEAR FUTURE	155
OFFSHORING AND LICENSING OPPORTUNITIES.....	156
STRATEGIC ENTRY AND CONTRIBUTION OF LOCAL, REGIONAL PLAYERS	156
RECOGNITION OF DISEASE PREVENTION BY KEY INTERNATIONAL STAKEHOLDERS.....	157
ERADICATION, ELIMINATION, AND RESURGENCE OF DISEASE RELATED TO VACCINATION	157
INCREASE IN PUBLIC-PRIVATE PARTNERSHIPS FUELLING GROWTH OF THE INDUSTRY.....	157
RECOGNITION OF VACCINE INITIATIVES IN AUXILLIARY SYSTEMS.....	158
ANIMAL VACCINES STUDIES AID HUMAN VACCINE DEVELOPMENT	158
VACCINATION AS A BETTER ALTERNATIVE TO LIVESTOCK SLAUGHTER	159
GROWTH INHIBITORS.....	159
TECHNICAL BARRIERS	159
REGULATORY BARRIERS	160
PATENT EXPIRY ISSUES.....	161
COMPLEXITY OF VACCINE DISTRIBUTION	161
GEOGRAPHICAL DIFFERENCES	161
NEED FOR SKILLED PERSONNEL AND/OR TRAINING	162
LACK OF INVOLVEMENT FROM PUBLIC AND LOCAL ADMINISTRATION	162
RELIGIOUS AND CULTURAL BARRIERS TO VACCINATION ...	163
ECONOMIC BARRIERS: AFFORDABILITY AND PERCEPTIONS OF COST	163
LACK OF AWARENESS AMONG POTENTIAL VACCINEES	164

Lack of Awareness...(Continued).....	165
VACCINE MARKET.....	166
SUPPLY SIDE.....	166
SUPPLY SIDE (CONTINUED)	167
PUBLIC VACCINE SUPPLY	168
VACCINE SHORTAGES	169
TABLE 60 CAUSES OF VACCINE SHORTAGE.....	170
DEMAND SIDE	171
FIRST ADVANCE MARKET COMMITMENT (AMC) IN	
FEBRUARY 2007.....	172
TABLE 61 SAVINGS FROM DISEASE ERADICATION (\$ BILLIONS)	172
PUBLIC FUNDING GAP.....	172
MARKET METRICS.....	173
TABLE 62 FORECAST FOR GLOBAL VACCINE REVENUE BY MAJOR	
SEGMENTS THROUGH 2013 (\$ MILLIONS).....	174
FIGURE 10 ANNUAL SPENDING FOR IMMUNIZATION PROGRAMS	
IN 72 LOW-INCOME COUNTRIES, 2000-2013 (\$ BILLIONS)	174
FIGURE 11 FORECAST FOR GLOBAL VACCINE REVENUES BY	
MAJOR SEGMENT, 2003-2013 (\$ MILLIONS)	175
TABLE 63 FORECAST FOR GLOBAL HUMAN VACCINE REVENUE,	
THROUGH 2013 (\$ MILLIONS).....	176
FIGURE 12 HUMAN VACCINES: MARKET POTENTIAL UNTILL 2013	177
TABLE 64 GLOBAL PROJECTIONS FOR MINOR HUMAN VACCINE	
REVENUE THROUGH 2013 (\$ MILLIONS).....	177
TABLE 64 (CONTINUED).....	178
TABLE 65 PROJECTIONS FOR GLOBAL CANCER VACCINES	
REVENUE, THROUGH 2013 (\$ MILLIONS).....	178
FIGURE 13 PROJECTIONS FOR GLOBAL CANCER VACCINES	
REVENUE, 2003-2013 (\$ MILLIONS)	179
VETERINARY VACINES	179
FIGURE 14 VETERINARY VACCINES: REGIONAL REVENUE	
CONTRIBUTION (%).....	180
TABLE 66 GLOBAL ANIMAL HEALTH REVENUES, 2006	
(\$ MILLIONS).....	181
FIGURE 15 GLOBAL ANIMAL HEALTH MARKET SHARES, 2006 (%).....	181
INDUSTRY PARTICIPANT PROFILES	182
MANUFACTURERS.....	182
ACAMBIS	182
BHARAT BIOTECH.....	182
TABLE 67 RESEARCH GRANTS FOR BHARAT BIOTECH.....	183
TABLE 68 PRODUCT PORTFOLIO — BHARAT BIOTECH	
INTERNATIONAL	183
CHOONGANG VACCINE LABORATORY.....	184

CRUCCELL.....	184
EUROCINE VACCINES AB.....	185
GLAXOSMITHKLINE	185
<i>TABLE 69 PORTFOLIO OF VACCINES: GLAXOSMITHKLINE</i>	<i>186</i>
GREEN CROSS.....	187
KOREA VACCINE CO, LTD.	187
<i>TABLE 70 VACCINE PORTFOLIO OF KOREA VACCINE</i>	<i>188</i>
MERCK & CO., INC.....	189
<i>TABLE 71 MERCK — VACCINE PORTFOLIO</i>	<i>189</i>
NOVARTIS AG.....	190
PANACEA BIOTEC, LTD.....	190
<i>TABLE 72 PRODUCT PORTFOLIO — PANACEA BIOTEC</i>	<i>191</i>
SANOFI PASTEUR.....	191
<i>TABLE 73 VACCINE PORTFOLIO: SANOFI PASTEUR</i>	<i>192</i>
SCHERING-PLOUGH CORPORATION	193
<i>TABLE 74 SCHERING-PLOUGH — PORTFOLIO OF LIVESTOCK</i> <i>VACCINES</i>	<i>193</i>
<i>TABLE 74 (CONTINUED)</i>	<i>194</i>
<i>TABLE 74 (CONTINUED)</i>	<i>195</i>
<i>TABLE 74 (CONTINUED)</i>	<i>196</i>
<i>TABLE 74 (CONTINUED)</i>	<i>197</i>
<i>TABLE 74 (CONTINUED)</i>	<i>198</i>
SHANTHA BIOTECHNICS	198
WYETH.....	199
<i>TABLE 75 PORTFOLIO OF VACCINES: WYETH PHARMACEUTICALS</i>	<i>200</i>
ADDITIONAL MARKET PLAYERS.....	200
ADVAXIC, INC.....	200
AERAS GLOBAL TB VACCINE FOUNDATION, USA.....	200
AGRILABS, INC.....	200
ALPHARMA INC.	201
BAYER ANIMAL HEALTH.....	201
BENCHMARK BIOLABS, INC.	201
BIMEDA	201
BIOCOR ANIMAL HEALTH.....	201
BIONICHE ANIMAL HEALTH	202
BIOPURE	202
BORYUNG BIOPHARMA	202
CEVA SANTE ANIMALE.....	202
COBRA BIOMANUFACTURING, PLC	202
CYTO DYN, INC.	203
DAINIPPON PHARMACEUTICAL CO, LTD.	203
DMS LABS, INC.....	203
DURVET, INC. USA	203
ELANCO ANIMAL HEALTH.....	203

HARTZ	203
HESKA CORPORATION.....	204
ICHOR MEDICAL SYSTEMS, INC.	204
IDEXX LABORATORIES, INC.	204
IMMUCELL, INC.....	204
IVY ANIMAL HEALTH	204
LAH INTERNATIONAL (GERMAN).....	204
MALAYSIAN VACCINES AND PHARMACEUTICALS	205
MONSANTO COMPANY.....	205
MWI VETERINARY SUPPLY CO.	205
NUTRAMAX LABORATORIES, INC.	205
OMAHA VACCINE	205
ROYER BIOMEDICAL, INC.	206
SK CHEMICAL	206
SOLVAY HEALTHCARE	206
SYNBIOTICS CORPORATION.....	206
VAXINE PTY, LTD.	206
VCA ANTECH.....	207
VEDCO, INC.	207
VIRBAC SA	207
XCELLEREX CORPORATE HEADQUARTERS	207
NONGOVERNMENT STAKEHOLDERS	207
DEPARTMENT OF IMMUNIZATION, VACCINES, AND BIOLOGICALS (IVB)	207
Initiative for Vaccine Research (IVR)	208
THE HIV VACCINE TRIALS NETWORK	209
<i>TABLE 76 HVTN OPERATIONAL CENTERS</i>	<i>210</i>
PROTECTING THE WORLD FROM EMERGING AND RE- EMERGING DISEASES ASSOCIATED WITH GLOBALIZATION	210
<i>TABLE 77 MAJOR INFECTIOUS DISEASE CATEGORIES AND LEADING SPONSORS</i>	<i>211</i>
GAVI	211
IAVI.....	212
THE WORLD ORGANIZATION FOR ANIMAL HEALTH (OIE)	213
REGULATORY ORGANIZATIONS CONCERNED WITH VETERINARY VACCINES.....	214
CENTERS FOR EPIDEMIOLOGY AND ANIMAL HEALTH.....	214
CENTER FOR VETERINARY BIOLOGICS.....	214
IFAH-EUROPE	214
INSTITUTE FOR INTERNATIONAL COOPERATION IN ANIMAL BIOLOGICS	214
INTERNATIONAL STANDARDS TEAM.....	215
NATIONAL VETERINARY SERVICES LABORATORIES.....	215

NATIONAL VETERINARY SERVICES LABORATORIES.....	215
UNITED STATES ANIMAL HEALTH ASSOCIATION	215
USDA NATIONAL ANIMAL HEALTH	215
RECENT INTERNATIONAL MARKET DEVELOPMENTS.....	216
GSK SEEKS APPROVAL FOR NEW MENINGITIS VACCINE	216
VACCINE FOR KEEPING THE BLOOD PRESSURE UNDER	
CHECK.....	216
VACCINE FOR NICOTINE ADDICTION.....	217
SCIENTISTS REPORT A NEW METHOD TO SPEED BIRD FLU	
VACCINE PRODUCTION	218
BIODEGRADABLE MICROSPHERES DELIVER TIME RELEASE	
VACCINES, STIMULATE DIFFERENT IMMUNE RESPONSE	218
NASAL SPRAY FLU VACCINE RECEIVES NOD FOR 2-YEAR-OLDS	
IN UNITED STATES	219
ONCOPHAGE FAILS TRIALS	219
NEW PRODUCTION FACILITY OF NOVARTIS' — CELL	
CULTURED-BASED FACILITY FOR INFLUENZA VACCINE	
PRODUCTION	220
XCELLEREX GETS TWO CONTRACTS TO DEVELOP	
TECHNOLOGY TO ACCELERATE PROTEIN AND VACCINE	
MANUFACTURING.....	220
DISPOSABLE TECHNOLOGIES — A BETTER PROSPECT	221
NEEDLE-FREE TECHNOLOGIES FOR VACCINE DELIVERY	222
FACTORY ZONE FOR ANIMAL VACCINE DEVELOPMENT AND	
PRODUCTION	223
CERUS CORPORATION AWARDED GRANTS FOR ITS LISTERIA-	
BASED VACCINE PLATFORMS.....	223
VACCINE MANUFACTURERS GET FUNDING TO DEVELOP	
CELL-BASED INFLUENZA VACCINES	224
CRUCCELL GRANTED \$5 MILLION TO FURTHER DEVELOP TB	
VACCINE.....	225
INTERNATIONAL ORGANIZATIONS COLLABORATE FOR A	
MENINGITIS VACCINE	226
THE ROLE OF THE U.S. FDA	227
FUTURE DIRECTIONS	227
EFFICIENT VACCINE MANUFACTURING: TREATMENT FOR	
MENINGOCOCCAL DISEASE IN AFRICA.....	227
PORTAL TO OFFER INFORMATION TO COMPILE INFORMATION	
ON INFECTIOUS DISEASES RESEARCH	228
TABLE 78 STRATEGIC ALLIANCES IN THE VACCINE INDUSTRY	229
TABLE 78 (CONTINUED).....	230
TABLE 78 (CONTINUED).....	231
TABLE 78 (CONTINUED).....	232
TABLE 78 (CONTINUED).....	233

TAIWAN — ANIMAL VACCINES INDUSTRY	233
<i>TABLE 79 R&D FOCUS</i>	234
TAIWAN — INVESTING OPPORTUNITIES	234
Strength	235
Weakness	235
Opportunity.....	235
Threat.....	235
CHINA.....	235
BIOTECHNOLOGY AND ITS SISTER TECHNOLOGIES LIGHT UP	
THE VACCINE FUTURE	236
INDIA	237
EDIBLE VACCINES.....	237